Antibiotic treatment inhibits paclitaxel chemotherapy-induced activity deficits in female mice.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
05
2022
accepted:
29
03
2023
medline:
15
5
2023
pubmed:
11
5
2023
entrez:
11
5
2023
Statut:
epublish
Résumé
Chemotherapy, a mainstay in the treatment of cancer, is associated with severe and debilitating side effects. Side effects can be physical (e.g., gastrointestinal distress, anemia, and hair loss) or mental (e.g., fatigue, cognitive dysfunction). Chemotherapy is known to alter the gut microbiota; thus, communication through the gut-brain axis may influence behavioral side effects. Here, we used a clinically-relevant paclitaxel chemotherapy regimen in combination with antibiotics to test the hypothesis that gut microbes contribute to chemotherapy-associated fatigue-like behaviors in female mice. Data presented suggest that chemotherapy-altered gut microbes contribute to fatigue-like behaviors in mice by disrupting energy homeostasis.
Identifiants
pubmed: 37167214
doi: 10.1371/journal.pone.0284365
pii: PONE-D-22-14575
pmc: PMC10174578
doi:
Substances chimiques
Paclitaxel
P88XT4IS4D
Anti-Bacterial Agents
0
Antineoplastic Agents
0
Banques de données
figshare
['10.6084/m9.figshare.20418951']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0284365Informations de copyright
Copyright: © 2023 Grant et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Curr Opin Endocrinol Diabetes Obes. 2021 Apr 1;28(2):243-252
pubmed: 33481425
Sci Rep. 2019 Nov 11;9(1):16490
pubmed: 31712703
Dig Dis. 2016;34(3):260-8
pubmed: 27028893
Curr Opin Pharmacol. 2019 Oct;48:82-91
pubmed: 31430598
Brain Behav Immun. 2014 Mar;37:84-94
pubmed: 24216337
Support Care Cancer. 2017 May;25(5):1563-1570
pubmed: 28064384
Behav Brain Res. 2021 Feb 5;399:113041
pubmed: 33279635
Brain Behav Immun. 2021 Jul;95:401-412
pubmed: 33895287
Clin Nutr. 2020 Jun;39(6):1863-1877
pubmed: 31420208
Neuropharmacology. 2017 May 1;117:305-315
pubmed: 28237807
Comp Med. 2011 Apr;61(2):119-30
pubmed: 21535922
Gut Pathog. 2019 Apr 30;11:18
pubmed: 31168325
Mol Neurodegener. 2021 Jun 26;16(1):41
pubmed: 34174909
Front Endocrinol (Lausanne). 2021 Jul 21;12:694204
pubmed: 34367066
Psychopharmacology (Berl). 2021 Dec;238(12):3357-3373
pubmed: 34498115
PLoS One. 2017 Oct 10;12(10):e0184360
pubmed: 29016607
PLoS One. 2011 Mar 21;6(3):e17996
pubmed: 21445311
Physiol Behav. 2021 Apr 1;232:113347
pubmed: 33529685
Lancet Oncol. 2019 Jun;20(6):769-780
pubmed: 31078462
J Endocrinol. 2019 Apr 1;241(1):R1-R33
pubmed: 30812013
Microbiome. 2016 Jun 23;4(1):30
pubmed: 27338587
Cancer Med. 2019 Jun;8(6):3227-3236
pubmed: 31012272
J Neurosci. 2007 Feb 14;27(7):1529-33
pubmed: 17301161
Endocrinology. 2013 Oct;154(10):3643-51
pubmed: 23892476
Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):4759-64
pubmed: 27071101
Oncologist. 2007;12 Suppl 1:4-10
pubmed: 17573451
PLoS One. 2013 May 28;8(5):e65465
pubmed: 23724144